COCPHIGH SIGNALOPERATIONAL10-K

COCP reported substantially reduced revenue and operating expenses alongside disappointing Phase 2a trial results for lead candidate CC-42344 due to unexpectedly low infection rates among study participants.

The company's clinical trial setback represents a significant operational challenge, as management explicitly stated that low infectivity hindered their ability to analyze antiviral efficacy data for their influenza treatment. The company has also shifted its strategic messaging from creating "first- and best-in-class" drugs to merely having "the goal of creating viable" treatments, suggesting tempered expectations for their development pipeline.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

COCP's financial profile contracted significantly across most metrics, with revenue declining substantially while R&D expenses were meaningfully reduced, likely reflecting the clinical trial challenges. Operating losses improved notably due to the lower expense base, though this appears driven by reduced activity rather than operational efficiency gains. The company's balance sheet weakened modestly with declining cash reserves and total assets, though stockholders' equity remained relatively stable at $6.3M.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-69.3%
$6.6M→$2.0M

Revenue declined 69.3% — significant demand weakness or market share loss warrants investigation.

R&D Expense
P&L
-59.7%
$12.5M→$5.1M

R&D spending cut 59.7% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
+50.3%
-$16.5M→-$8.2M

Operating cash flow surged 50.3% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
+50%
$8K→$12K

Capital expenditure jumped 50% — major investment cycle underway; assess returns on deployment.

Operating Income
P&L
+49.6%
-$17.9M→-$9.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+49.5%
-$17.5M→-$8.8M

Net income grew 49.5% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-33.5%
$9.5M→$6.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-29.8%
$11.6M→$8.1M

Current assets declined 29.8% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-28.8%
$9.9M→$7.0M

Cash decreased 28.8% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
-27.8%
$13.5M→$9.7M

Total assets contracted 27.8% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
We employ unique structure-based technologies and Nobel Prize winning expertise with the goal of creating viable antiviral drugs.
As of late 2025, the prevalent variants of COVID-19 were KP.3.1.1, LP.8.1, NB1.8.1, XFG, and BA.3.2, four of which emerged in 2025.
These five variants are variants under monitoring (VUM) by the World Health Organization as of February 2026 due to their increasing prevalence globally.
Research and Development Update During the 12 months ended December 31, 2025 the Company continued to focus its research and development efforts primarily in three areas.
This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, viral and clinical measurements of healthy subjects infected with the influenza A virus dosed with oral CC-42344 treatment.
While in the Phase 2a study CC-42344 demonstrated favorable safety and tolerability profile and no serious adverse events ( SAEs ) or drug-related discontinuations by study participants, due to unexpectedly low influenza infection among study participants, management determined that the low infectivity obtained in this study hindered antiviral data analysis.
A dispute has arisen with the United Kingdom clinical research organization (the CRO ) that performed the Phase 2a study.
The Company contends that the CRO breached its agreement in a number of respects and is requesting that the CRO refund the $6,309,000 it was paid or redo the study.
The CRO has implicitly denied liability and is seeking to recover an additional approximately $600,000 from the Company.
As of the date of this Report, it appears that the Company will seek to arbitrate the dispute as required under the agreement with the CRO.
REMOVED
We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
As of early 2025, the prevalent variants of COVID-19 were XEC and LP.8.1, each of which emerged in 2024.
These two variants are variants under monitoring (VUM) by the World Health Organization as of February 2025 due to their increasing prevalence globally.
Research and Development Update During the twelve months ended December 31, 2024 the Company continued to focus its research and development efforts primarily in three areas.
This randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment.
In May 2024 we announced completion of enrollment of 78 subjects.
In December 2024, the Company announced plans to extend enrollment for the oral CDI-42344 Phase 2a study due to unexpectedly low influenza infection among study participants.
Specifically, management determined that an extension of the study is necessary due to low infectivity rate of the challenge influenza strain used in this study, as the establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecule, and the low infectivity obtained in this study hindered antiviral data analysis.
The Company is currently in continuing discussions with the clinical research organization to address this study and determine a course forward with respect thereto, including potentially by preparing a protocol amendment or a resubmission for approval by the United Kingdom Medicines and Healthcare Products Regulatory Agency ( MHRA ) in order to seek enrollment to study and to ensure necessary infection rates among enrolled study subjects in the study.
CC-42344 has demonstrated favorable safety and tolerability profile from the Phase 2a study to date, with no SAEs and no drug-related discontinuations by study participants.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →